PSYLO 3002
Alternative Names: Psylo-3002Latest Information Update: 21 Jul 2023
At a glance
- Originator Psylo
- Class Drug withdrawal therapies; Neuropsychotherapeutics; Obesity therapies
- Mechanism of Action 5-HT2C serotonin receptor modulators; Serotonin 5-HT2A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity; Substance-related disorders
Most Recent Events
- 13 Jul 2023 Preclinical trials in Obesity in Australia (unspecified route) prior to July 2023 (Psylo pipeline, July 2023)
- 13 Jul 2023 Preclinical trials in Substance-related disorders in Australia (unspecified route) prior to July 2023 (Psylo pipeline, July 2023)